Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition

Cancers expressing mutant RAS are associated with a weaker response to chemotherapy and a shorter overall patient survival. We have demonstrated that the irreversible inhibitor of ERBB1/2/4, neratinib, inhibits ERBB1/2/4 and causes their internalization and autolysosomal degradation. Fellow-traveler...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Biol Ther
Auteurs principaux: Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Cutler, Richard E., Diala, Irmina, Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2018
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6343717/
https://ncbi.nlm.nih.gov/pubmed/30183517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1507665
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires